Breast cancer is the most common malignant tumor in women. Optimization of complex treatment schemes for patients with breast cancer has been the subject of many discussions so far. Systemic adjuvant therapy, including hormone therapy, is used to reduce the frequency of relapses and the development of remote tumor foci. However, breast cancer still accounts for 20 percent of all female cancer deaths.
Arecur® contains regulatory peptides of natural origin RJP-1 and defensin-1, is capable of preventing recurrences and metastases after surgical removal of the tumor and chemotherapy.
Observations showed that in the group of patients who took exogenous peptides, within 24 months of observation, there was a significant increase in relapse-free survival, as well as a decrease in the risk of relapses and metastases for the specified period by 71.8% – Hazard ratio (95% CI) = 0.292 ( 0.094 – 0.907), p = 0.046.